ReviewPharmaceutics2021
Current Insights Into 3D Bioprinting: An Advanced Approach for Eye Tissue Regeneration.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Ethical Implications of Tissue Engineering for Regenerative Purposes: A Systematic Review.Tissue engineering. Part B, Reviews · 2023Pooled it
- Three-dimensional tissue engineering and organoid technologies for retinal regeneration and therapy.Bioengineering & translational medicine · 2025Review
- Applications of Modern Cell Therapies: The Latest Data in Ophthalmology.Life (Basel, Switzerland) · 2025Review
- Fabrication of a 3D Corneal Model Using Collagen Bioink and Human Corneal Stromal Cells.Journal of functional biomaterials · 2025Article
- Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology.International ophthalmology · 2025Review
- 3D Bioprinting of Cellular Therapeutic Systems in Ophthalmology: from Bioengineered Tissue to Personalized Drug Delivery.Current ophthalmology reports · 2025Review
- The Promise and Challenges of Bioprinting in Tissue Engineering.Micromachines · 2024Article
- Three-Dimensional Bioprinting for Retinal Tissue Engineering.Biomimetics (Basel, Switzerland) · 2024Review
- Advancements in Hydrogels for Corneal Healing and Tissue Engineering.Gels (Basel, Switzerland) · 2024Review
- Three-Dimensional Bioprinting: A Comprehensive Review for Applications in Tissue Engineering and Regenerative Medicine.Bioengineering (Basel, Switzerland) · 2024Review
- 3D printing sequentially strengthening high-strength natural polymer hydrogel bilayer scaffold for cornea regeneration.Regenerative biomaterials · 2024Article
- The Innovative Biomaterials and Technologies for Developing Corneal Endothelium Tissue Engineering Scaffolds: A Review and Prospect.Bioengineering (Basel, Switzerland) · 2023Review
- Technical Feasibility of Whole-eye Vascular Composite Allotransplantation: A Systematic Review.Plastic and reconstructive surgery. Global open · 2023Article
- 3D bioprinting of corneal decellularized extracellular matrix: GelMA composite hydrogel for corneal stroma engineering.International journal of bioprinting · 2023Article
- Three-dimensional bioprinting in ophthalmic care.International journal of ophthalmology · 2023Review
- Progress in 3D Bioprinting Technology for Osteochondral Regeneration.Pharmaceutics · 2022Review
- Application of Bioprinting in Ophthalmology.International journal of bioprinting · 2022Review
- 3D Printing in Eye Care.Ophthalmology and therapy · 2021Review
- Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges.Pharmaceutics · 2021Article
- Bioprinting Technology in Skin, Heart, Pancreas and Cartilage Tissues: Progress and Challenges in Clinical Practice.International journal of environmental research and public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Three-dimensional (3D) printing is a game changer technology that holds great promise for a wide variety of biomedical applications, including ophthalmology. Through this emerging technique, specific eye tissues can be custom-fabricated in a flexible and automated way, incorporating different cell types and biomaterials in precise anatomical 3D geometries. However, and despite the great progress and possibilities generated in recent years, there are still challenges to overcome that jeopardize its clinical application in regular practice. The main goal of this review is to provide an in-depth understanding of the current status and implementation of 3D bioprinting technology in the ophthalmology field in order to manufacture relevant tissues such as cornea, retina and conjunctiva. Special attention is paid to the description of the most commonly employed bioprinting methods, and the most relevant eye tissue engineering studies performed by 3D bioprinting technology at preclinical level. In addition, other relevant issues related to use of 3D bioprinting for ocular drug delivery, as well as both ethical and regulatory aspects, are analyzed. Through this review, we aim to raise awareness among the research community and report recent advances and future directions in order to apply this advanced therapy in the eye tissue regeneration field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.